Abstract: The invention pertains to the use of a composition in the manufacture of a product or method for therapeutically improving, promoting, restoring or maintaining recognition and/or working memory in a subject suffering from PKU and/or in a subject suffering from or at increased risk of impaired recognition and/or working memory associated with PKU, said composition comprising therapeutic amounts of: (i) at least one ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) choline, a choline salt and/or choline ester; and (iii) at least one B vitamin selected from the group consisting of vitamin B6, vitamin B12 and vitamin B9, including functional equivalents thereof, preferably vitamin B6 and/or vitamin B12, and functional equivalents thereof. The invention also pertains to a composition for use in such use or method.

Abstract: The present invention relates to formulae for infants comprising milk fat for rendering the growth trajectory or body development during the first year of life more similar to that observed for human milk fed infants.

Abstract: A tearable foil for closing a package comprises a plurality of layers laminated together, including at least an oxygen barrier layer and a cover layer. A tear line penetrates at least partially through the cover layer to define a tear strip extending from a pull tab to a tail, wherein the pull tab comprises lateral wings that are delaminated with respect to the remainder of the foil, on either side of a central region that is laminated to the remainder of the foil. A user may fold the lateral wings together at right angles to a plane of the foil and grip them to exert a force on the central region and thus commence tearing of the tear strip.

Abstract: The present invention relates to formulae for infants comprising large lipid globules and/or lipid globules with a coating of phospholipids for rendering the growth trajectory or body development during the first year of life more similar to that observed for human milk fed infants.

Abstract: Heat-treated liquid enteral nutritional composition with a low monovalent metal ion content are provided that contain micellar casein and optionally caseinate, and in which the total amount of monovalent metal ions is less than 25 mg/g of protein. Also, heat-treated liquid enteral nutritional compositions are disclosed comprising 10 to 20 g of protein per 100 ml of the composition, in which all or a major part of said protein comprises micellar casein. Also, a method is disclosed for producing the composition according to the invention, comprising a step wherein an aqueous protein solution in which all or a major part of said protein comprises micellar casein, is subjected to an evaporation step.

Abstract: The invention pertains to a method for improving or promoting equilibrioception or coordination and balance in a healthy subject, comprising administration of: (i) ?-3 polyunsaturated fatty acid (LCPUFA) selected from the group consisting of docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA) and docosapentaenoic acid (DPA); (ii) one of more of uridine, cytidine and/or an equivalent thereof, including salts, phosphates, acyl derivatives and/or esters; and (iii) free leucine, to said healthy subject. The invention also pertains to a composition for use in such a method.

Abstract: The invention concerns nutritional compositions with fucosyllactose for use in stimulation of NK cells. The composition is suitable for infants.

Abstract: The invention relates to a composition comprising: i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof; ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaenoic acid (20:5; EPA) and docosapentaenoic acid (22:5; DPA), or esters thereof, in which the lipid fraction comprises less than 2 weight % of ?-linolenic acid (ALA), calculated on the weight of all fatty acids; iii) choline, or salts or esters thereof; for use in the prevention or treatment of neurotrauma, traumatic brain injury, cerebral palsy and spinal cord injury.

Abstract: A composition comprising Bifidobacterium breve, a non-digestible saccharide A and a non-digestible saccharide B, optionally combined with Lactobacillus paracasei and the use of said composition for the treatment and/or prevention of gastro-intestinal disorder, immune disorder and/or endocrine disorder.

Abstract: A collapsible bottle for enteral feed has a thin-walled body extending axially from a base to a neck and having a front, a back and two sides that define a width dimension of the bottle. The body has a shoulder region adjacent to the neck, a hip region adjacent to the base and a waist region therebetween and the circumference of the bottle in the waist region is less than the circumference of the bottle in both the hip region and the shoulder region. The bottle is provided with hinge columns that extend between the hip region and the shoulder region at the sides of the bottle. The hinge columns provide the wall of the body with a region of increased stiffness in the axial direction while facilitating bending of the wall about the hinge column.

Abstract: The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal.

Abstract: The present invention relates to food compositions comprising nutritional composition for use in the treatment or nutritional management of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or hyperphenylalaninemia. The composition comprises a specific protein source, long chain polyunsaturated fatty acids and at least one of uridine or cytidine.

Abstract: A package for a powdered nutritional product comprises a container for receiving the nutritional product, having a base and a peripheral wall. A lid assembly comprises a circumferential rim, defining an access opening, for connection to the container and a lid, pivotably attached to the rim by at least one hinge having a hinge axis. The lid has an open position and a closed position in which it closes the access opening. The hinge comprises a rim portion, integral with the rim, and a lid portion, integral with the lid, that can be engaged to each other to join the lid to the rim. The hinge is are arranged such that the lid portion can only be engaged with the rim portion in the open position of the lid. In the closed position of the lid, the lid portion is locked to the rim portion, preventing separation of the lid portion from the rim portion. The hinge is also arranged to prevent opening of the lid beyond a point at which the package is unstable.

Abstract: The invention relates to a process for treating animal skim milk and sweet whey and/or acid whey, having: (a) ultrafiltration (UF1) of a first liquid composition including animal skim milk with 70-90 wt % casein and 10-30 wt % whey proteins, based on total protein, over a first ultrafiltration membrane having a molecular weight cut-off of 2.5-25 kDa using a volume concentration factor of 1.5-6 to obtain a retentate (UFR1) and a permeate (UFP1); (b) ultrafiltration (UF2) of a second liquid composition including sweet whey and/or acid whey over a second ultrafiltration membrane having a molecular weight cut-off of 2.5-25 kDa using a volume concentration factor of 2-15 to obtain a retentate (UFR2) and a permeate (UFP2); and (c) mixing the UF retentate originating from step (a) with the UF retentate originating from step (b) to obtain a mixture of UF retentates.

Abstract: A process and system is shown for obtaining a dry milk formula, having (a-i) ultrafiltration of an animal skim milk composition having 70-90 wt % casein and 10-30 wt % whey proteins, based on total protein, and (a-ii) ultrafiltration of an animal whey composition having 0-25 wt % casein and 75-100 wt % whey proteins, based on total protein; or (a-iii) ultrafiltration of a mixture of the compositions of (a-i) and (a-ii), (b) removing polyvalent ions from the UF permeate originating from step (a-i) and/or (a-ii) or (a-iii) to obtain at least one softened UF permeate; (c) combining the at least one softened UF permeate with a UF retentate to obtain a combined product; and (d) drying the combined product to obtain a dry milk formula.

Abstract: The present invention relates to the field of prebiotics. Provided are uses for compositions comprising synergistically effective amounts of polyfructose and galactooligosaccharides (GOS).

Abstract: The invention relates to nutritional compositions with Bifidobacterium breve and non-digestible oligosaccharides selected from the group consisting of fructo-oligosaccharides, galacto-oligosaccharides, gluco-oligosaccharides, arabino-oligosaccharides, mannan-oligosaccharides, xylo-oligosaccharides, fuco-oligosaccharides, arabinogalacto-oligosaccharides, glucomanno-oligosaccharides, galactomanno-oligosaccharides, sialic acid comprising oligosaccharides and uronic acid oligosaccharides for use in improving cognitive or behavioral performance, cognitive or behavioral development, social interaction and/or neuroinflammation in infants or toddlers. Also claimed is the use of a nutritional compositions including Bifidobacterium breve, at least one non digestible oligosaccharide, glutamine in the form of free amino acids and/or glutamine containing dipeptide and/or glutaime containing tripeptide and LC-PUFA in the form or arachidonic acid and/or docosahexaenoic acid.

Abstract: This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 ?M in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes.

Abstract: The invention pertains to the use of a composition comprising per serving between 50-300 kcal; between 10 g and 35 g proteinaceous matter; and at least 2.5 microgram vitamin D, for the manufacture of a nutritional product for (a) the treatment or prevention of muscle mass decrease, (b) stimulation of muscle mass increase; or (d) stimulating muscle mass preservation, in obese or overweight adults of at least 40 years of age participating in a weight loss program. The inventors surprisingly found that nutritional supplementation with a low-caloric composition rich in protein, particularly whey protein and leucine, compared to an iso-caloric control supplement without protein, synergistically leads to preservation of muscle mass during a weight loss program involving a hypocaloric diet and a resistance exercise program in overweight/obese older adult.